Lilly’s Multi-Tumor Treatment Retsevmo Closer To EU Approval

Set For First-In-Class Status

 
• By Andrew McConaghie
  
Eli Lilly
Retevmo has another RET-targeting drug hot on its heels, Roche and Blueprint's Gavreto, which gained US approval in September.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip